The International Journal of Molecular and Immuno Oncology (IJMIO) is an open-access peer-reviewed journal committed to publishing high-quality articles in the field of Molecular Biological and Immunological aspects of Oncology. The journal is owned by the Alms Tech LLP and published by the Scientific Scholar.
IJMIO is a peer-reviewed 3 (three) issues journal that is published both online and in print jointly by Molecular Oncology Society (http://www.moscon.info) and Immuno Oncology Leadership Network (https://www.oncologylion.com). It is published by Scientific Scholar. The journal’s full text is available online at (https://ijmio.com). IJMIO is an Open Access journal, and online access to full text articles is provided at no charge for non-commercial use. The journal does not charge for submission or acceptance of manuscripts.
IJMIO employs the highest standards in publishing, backed by the years of experience of the Molecular Oncology Society and Immuno Oncology Leadership Network. The journal follows stringent peer-review and editorial policies that allow for the selection of high quality work to be published. All manuscripts are evaluated by peer-review for their quality of science (including novelty, technical methodology, and integrity). The editorial policy is to require all authors to disclose any relevant financial associations and declare that financial interests have not influenced the content of the manuscript being published. This is in keeping with the high ethical standards we strive to ensure for all work published in IJMIO.
Focus and Scope
The International Journal of Molecular and Immuno Oncology (IJMIO) is dedicated to providing a platform for highlighting novel and relevant research and exchange of knowledge at the crossroads of bench and bedside research. The goal is to provide information in an understandable format for clinicians and keep up with the fast-paced developments in Molecular Biology and Immunology related to Oncology.
Our audience includes Molecular Oncologists, Immunologists, medical professionals and students.
IJMIO has a highly rigorous peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts, affiliations and financial associations such that the published content is not biased.
The editorial board comprises of a panel of international experts in Molecular and Immuno Oncology from around the globe. Our editorial board members provide their expertise and guidance in shaping the content and direction of the journal.
About the Editor
Dr. Purvish M. Parikh MD, DNB, FICP, PHD, ECMO, CPI, MBA
Dr. Purvish M. Parikh is,
1. Director of Precision Oncology & Research, Asian Cancer Institute
2. Board Member, Maharashtra University of Health Sciences
3. Executive Director, Indian Cooperative Oncology Network
4. Director of Clinical Research and Education, BSES Municipal Hospital
5. Past President, SAARC Federation for Oncologists
6. Past President, Indian Society of Medical & Pediatric Oncology
7. Emeritus Editor, South Asian Journal of Cancer & International Journal of Molecular and Immuno-Oncology.
8. Passionate about Digital Health & Medico-Legal Issues.
9. Unconventional Educator
10.Author of 19 books; 36 chapters in books; 200+ scientific articles
Dr. Randeep Singh MD, DM, ECMO, FCCP
Dr. Singh currently is working as a Senior consultant and unit head at Artemis hospitals, Gurugram. He also owns the ONCOMED clinic at Hauz Khas, Delhi. He has been trained extensively in the management of cancer patients at the prestigious Tata Memorial Hospital (TMH), Mumbai. He did his Doctorate (DM: Medical Oncology) from Tata Memorial Hospital, Mumbai and then worked as a consultant at TMH, Mumbai with the solid tumor-working group before joining the Max group of hospitals. He worked as a Consultant with Max Healthcare for five years. Thereafter he was heading the Department of Medical Oncology at HCG cancer center, Delhi before joining ARTEMIS Hospitals, Gurgaon. His key area of interest is lung cancer, gastrointestinal and breast cancer.
Dr. Singh has more than 40 publications in national and international journals of high impact factor. He has also attended and presented various scientific papers in national and international journals. He is a distinguished faculty at various national and international conferences. He currently serves as Joint Secretary at Indian Society Medical & Pediatric Oncology (ISMPO). He is a co-founder member of International CME organization and executive member of various national organization’s such as ICON (Indian Co-Operative Oncology Network), ISMPO (Indian Society of Medical & Pediatric Oncology), Delhi Oncology Forum. He is also associated with international societies such as ESMO (European Society of Medical Oncology) & ASCO (American Society of Clinical Oncology)
Facts about the Journal
Scope of the journal
IJMIO is a peer-reviewed journal that highlights the latest developments, approaches, and discoveries in basic, clinical and translational oncology. The journal reviews and accepts original clinical and laboratory-based research manuscripts as well as invited reviews focused on molecular biological and immunological aspects of oncology. Articles addressing contemporary advances and challenges faced in molecular and immune-oncology in developing nations are also strongly encouraged.
Key areas covered by the journal include
- Biomarkers and individualized therapy
- Nanotechnology and other technological advances
- Cancer genetics and epigenetics
- Cancer microenvironment and cell biology
- Immunological aspects of tumorigenesis
- Molecular and immunological therapies
- Clinical trials
This journal publishes manuscripts in the following sections
- Original Articles
- Case Reports
- Review Articles
- Educational Forum
- New Drug Update
- Letter to the Editor
- Short Communication
- Brief Commentary
- Consensus Statement
All manuscripts submitted through all the sections are peer-reviewed prior to acceptance. It is a peer-reviewed international journal with a double-blind review process. Its frequency of publication is 3 (three) issues per year. The Journal is published both online and in print.
An article published in the journal can be viewed without a fee by readers all over the world. The author also gets to retain copyright to the article and the figures. This allows authors to extend their exposure in the world of medical research and get worldwide recognition for their work.
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Google Scholar, CrossRef, ReadCube, National Science Library, Index Copernicus, International Committee of Medical Journal Editors (ICMJE)
The International Journal of Molecular and Immuno Oncology is committed to meeting and upholding the standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit our Ethical Guidelines section
We have plagiarism check available on our Editors and Reviewer’s panel in the manuscript management system. We encourage our editors and reviewers to use the plagiarism check. Any manuscript with plagiarism will be rejected immediately.
We use PORTICO for our third-party repository for all articles published with us. All our articles are assigned a DOI number. We are members of https://crossref.org
Open Access Publication and Creative Commons Licensing
This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Ahead of Print policy
Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. International Journal of Molecular and Immuno Oncology has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.
While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content are not biased or influenced by the advertisement.
“Pop-up” and “banner” advertisement appears at a fixed location on the page and does not interfere with the manuscript in any form.
The Editorial Board has full and final approval over the content of all advertisements.
Advertisers will never be shown any manuscripts or other content prior to publication.
Copies are provided free to members of the journal’s institution.
For non-members, please log on to https://scientificscholar.com/buy-subscriptions
Scientific Scholar, USA, established with the aim of publishing scientific journals. The mission of the company is “Share, Learn and Improve”.
Beginning in 2017, scientific journal publishing bought under the new umbrella of “Scientific Scholar”.
Imaging Science Today was founded in 2011 by a group of practicing doctors and industry specialists. It is a well-respected medical publisher that fully supports many of the popular open access models and all the aspects of the scientific journal publishing through its peer-review management system – Scientific Scholar and Open Access platform. The headquarter of Scientific Scholar is in Rochester, NY, USA and has a subsidiary arm in India.
Scientific Scholar currently publishes prestigious journals like the American Journal of Sonography and American Journal of Ophthalmic Clinical Trials and is growing in its portfolio.